Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NACDS Marketplace In Brief: SnapBack

This article was originally published in The Tan Sheet

Executive Summary

SnapBack: Stimulant powder by Salisbury, N.C.-based Stanback Co., makers of StanBack aspirin headache powder, will ship July 1 to mass retailers and drug stores, as well as college campus stores and truckstops. A 16-packet package will retail for about $2.29; a four-packet size will sell for about 99 [cents]. The powders, containing 200 mg caffeine each, will appeal to college students, truckdrivers and shift workers, the company says, and will be advertised on late night radio. SnapBack is the "fastest acting alertness aid on the market," a trade show promotional product brochure claims. Packaging is bright pink with yellow highlights; a flag on the box proclaims: "Ultra fast stimulant." The powder is "ultra fast acting," "easy to take" and "safe as coffee," consumer packaging states...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel